All In Biotech

Drug Trial Radar · NCT06669247

A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma

A First-in-Human (FIH) Phase 1/2 Study to Assess Safety, Tolerability, and Preliminary Anti-Tumor Activity of REGN7945, an Anti-CD38 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination With Linvoseltamab, an Anti-BCMA x Anti-CD3 Bispecific Monoclonal Antibody, in Participants With Relapsed/Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

186

Planned (sponsor's estimate)

Start

Dec 11, 2024

Primary completion

Nov 11, 2033

Study completion Nov 1, 2035

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Nov 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called REGN7945 in combination with another experimental drug called linvoseltamab, (also known as REGN5458) (each individually called a "study drug" or "study drugs" when combined). This study is the first time REGN7945 will be tested in humans. Linvoseltamab has previously been studied by itself (without other cancer drugs) in participants who had advanced multiple myeloma that returned and needed to be treated again after several other therapies had failed. The aim of the study is to see how safe, tolerable, and effective REGN7945 is when given in combination with linvoseltamab, compared with linvoseltamab alone. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug(s) * How many people treated with REGN7945 and linvoseltamab compared to linvoseltamab alone have improvement of their multiple myeloma and by how much * How long people benefit from receiving REGN7945 in combination with linvoseltamab compared with linvoseltamab alone * How much study drug(s) is in the blood at different times * Whether the body makes antibodies against the study drugs(s) (which could make the study drug(s) less effective or could lead to side effects) * If there is any change in pain and cancer-related symptoms, how well people are able to function, and their quality of life when taking the study drug(s)

Conditions

  • Relapsed/Refractory Multiple Myeloma

Interventions

  • LinvoseltamabDrug

    Administered per protocol

  • REGN7945+LinvoseltamabDrug

    Administered per protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose limiting toxicities (DLTs) from the first dose of REGN7945 in combination with linvoseltamabTime frame: Up to 21 days
  2. Incidence of treatment emergent adverse events (TEAEs) during the treatment period with REGN7945 in combination with linvoseltamabTime frame: Up to 5 years
  3. Severity of TEAEs during the treatment period with REGN7945 in combination with linvoseltamabTime frame: Up to 5 years
  4. Very Good Partial Response (VGPR) or better as determined by the investigator using the International Myeloma Working Group (IMWG) response criteria in patients receiving combination therapyTime frame: Within 12 weeks of starting cycle 1
  5. VGPR or better as determined by the investigator using the IMWG response criteria in patients receiving linvoseltamab monotherapyTime frame: Within 12 weeks of starting cycle 1
  6. Partial Response (PR) or better as determined by the investigator using the IMWG response criteria in patients receiving combination therapyTime frame: Within 12 weeks of starting cycle 1
  7. PR or better as determined by the investigator using the IMWG response criteria in patients receiving linvoseltamab monotherapyTime frame: Within 12 weeks of starting cycle 1

Locations

9 sites in 2 countries. Site status is shown where the registry gives one.

  • Royal Prince Alfred Hospital

    Sydney, New South Wales, Australia · Recruiting

  • Illawarra Cancer Care Centre

    Wollongong, New South Wales, Australia · Recruiting

  • Pindara Private Hospital

    Benowa, Queensland, Australia · Recruiting

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia · Recruiting

  • Alfred Hospital

    Melbourne, Victoria, Australia · Recruiting

  • St Vincents Hospital Melbourne

    Melbourne, Victoria, Australia · Recruiting

  • University College London Hospitals

    London, United Kingdom · Recruiting

  • St Thomas Hospital

    London, United Kingdom · Recruiting

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.